0 6 SLP-76 SLP-76 NNP 7 10 and and CC 11 14 Vav Vav NNP 15 23 function function NN 24 26 in in IN 27 35 separate separate JJ 35 36 , , , 37 40 but but CC 41 52 overlapping overlap VBG 53 61 pathways pathway NNS 62 64 to to TO 65 72 augment augment VB 73 86 interleukin-2 interleukin-2 NN 87 95 promoter promoter NN 96 104 activity activity NN 104 105 . . . 107 113 SLP-76 SLP-76 NNP 114 117 and and CC 118 121 Vav Vav NNP 121 122 , , , 123 126 two two CD 127 140 hematopoietic hematopoietic JJ 141 145 cell cell NN 146 154 specific specific JJ 155 164 molecules molecule NNS 164 165 , , , 166 169 are be VBP 170 178 critical critical JJ 179 182 for for IN 183 184 T t NN 185 189 cell cell NN 190 201 development development NN 202 205 and and CC 206 216 activation activation NN 216 217 . . . 218 227 Following follow VBG 228 229 T t NN 230 234 cell cell NN 235 242 antigen antigen NN 243 251 receptor receptor NN 252 263 stimulation stimulation NN 263 264 , , , 265 271 SLP-76 SLP-76 NNP 272 275 and and CC 276 279 Vav Vav NNP 280 284 both both DT 285 292 undergo undergo VBP 293 301 tyrosine tyrosine NN 302 317 phosphorylation phosphorylation NN 318 321 and and CC 322 331 associate associate VBP 332 336 with with IN 337 341 each each DT 342 347 other other JJ 348 351 via via IN 352 355 the the DT 356 359 SH2 sh2 NN 360 366 domain domain NN 367 369 of of IN 370 373 Vav Vav NNP 374 377 and and CC 378 392 phosphorylated phosphorylate VBN 393 402 tyrosines tyrosine NNS 403 405 of of IN 406 412 SLP-76 SLP-76 NNP 412 413 . . . 414 425 Furthermore furthermore RB 425 426 , , , 427 433 SLP-76 SLP-76 NNP 434 437 and and CC 438 441 Vav Vav NNP 442 446 have have VBP 447 448 a a DT 449 460 synergistic synergistic JJ 461 467 effect effect NN 468 470 on on IN 471 482 interleukin interleukin NN 483 484 ( ( ( 484 489 IL)-2 il)-2 NN 490 498 promoter promoter NN 499 507 activity activity NN 508 510 in in IN 511 512 T t NN 513 518 cells cell NNS 518 519 . . . 520 522 In in IN 523 527 this this DT 528 534 report report NN 534 535 , , , 536 538 we we PRP 539 543 show show VBP 544 548 that that IN 549 552 two two CD 553 562 tyrosines tyrosine NNS 562 563 , , , 564 571 Tyr-113 tyr-113 NN 572 575 and and CC 576 583 Tyr-128 tyr-128 NN 583 584 , , , 585 587 of of IN 588 594 SLP-76 SLP-76 NNP 595 598 are be VBP 599 607 required require VBN 608 611 for for IN 612 615 its its PRP$ 616 623 binding binding NN 624 626 to to TO 627 630 Vav Vav NNP 630 631 , , , 632 636 both both CC 637 639 in in FW 640 645 vitro vitro FW 646 649 and and CC 650 652 in in IN 653 659 intact intact JJ 660 665 cells cell NNS 665 666 . . . 667 679 Surprisingly surprisingly RB 679 680 , , , 681 683 we we PRP 684 688 find find VBP 689 693 also also RB 694 698 that that IN 699 702 the the DT 703 714 interaction interaction NN 715 722 between between IN 723 729 SLP-76 SLP-76 NNP 730 733 and and CC 734 737 Vav Vav NNP 738 740 is be VBZ 741 744 not not RB 745 753 required require VBN 754 757 for for IN 758 763 their their PRP$ 764 775 cooperation cooperation NN 776 778 in in IN 779 789 augmenting augment VBG 790 794 IL-2 il-2 NN 795 803 promoter promoter NN 804 812 activity activity NN 812 813 , , , 814 816 as as IN 817 820 the the DT 821 824 two two CD 825 834 molecules molecule NNS 835 841 appear appear VBP 842 844 to to TO 845 853 function function VB 854 856 in in IN 857 866 different different JJ 867 876 signaling signaling NN 877 885 pathways pathway NNS 886 894 upstream upstream JJ 895 897 of of IN 898 902 IL-2 il-2 NN 903 907 gene gene NN 908 918 expression expression NN 918 919 . . . 920 934 Overexpression Overexpression NNP 935 937 of of IN 938 944 SLP-76 SLP-76 NNP 945 947 in in IN 948 951 the the DT 952 958 Jurkat Jurkat NNP 959 960 T t NN 961 965 cell cell NN 966 970 line line NN 971 982 potentiates potentiate VBZ 983 986 the the DT 987 997 activities activity NNS 998 1000 of of IN 1001 1005 both both CC 1006 1013 nuclear nuclear JJ 1014 1020 factor factor NN 1021 1023 of of IN 1024 1033 activated activate VBN 1034 1035 T t NN 1036 1041 cells cell NNS 1042 1045 and and CC 1046 1050 AP-1 ap-1 NN 1051 1064 transcription transcription NN 1065 1072 factors factor NNS 1072 1073 . . . 1074 1076 In in IN 1077 1085 contrast contrast NN 1085 1086 , , , 1087 1101 overexpression overexpression NN 1102 1104 of of IN 1105 1108 Vav Vav NNP 1109 1114 leads lead VBZ 1115 1117 to to TO 1118 1126 enhanced enhance VBN 1127 1134 nuclear nuclear JJ 1135 1141 factor factor NN 1142 1144 of of IN 1145 1154 activated activate VBN 1155 1156 T t NN 1157 1162 cells cell NNS 1163 1171 activity activity NN 1172 1179 without without IN 1180 1189 affecting affect VBG 1190 1194 AP-1 ap-1 NN 1194 1195 . . . 1196 1208 Additionally additionally RB 1208 1209 , , , 1210 1224 overexpression overexpression NN 1225 1227 of of IN 1228 1231 Vav Vav NNP 1231 1232 , , , 1233 1236 but but CC 1237 1240 not not RB 1241 1247 SLP-76 SLP-76 NNP 1247 1248 , , , 1249 1257 augments augment VBZ 1258 1270 CD28-induced cd28-induced JJ 1271 1275 IL-2 il-2 NN 1276 1284 promoter promoter NN 1285 1293 activity activity NN 1293 1294 . . . 1295 1300 These these DT 1301 1309 findings finding NNS 1310 1317 suggest suggest VBP 1318 1322 that that IN 1323 1326 the the DT 1327 1334 synergy synergy NN 1335 1342 between between IN 1343 1349 SLP-76 SLP-76 NNP 1350 1353 and and CC 1354 1357 Vav Vav NNP 1358 1360 in in IN 1361 1371 regulating regulate VBG 1372 1376 IL-2 il-2 NN 1377 1381 gene gene NN 1382 1392 expression expression NN 1393 1401 reflects reflect VBZ 1402 1405 the the DT 1406 1417 cooperation cooperation NN 1418 1425 between between IN 1426 1435 different different JJ 1436 1445 signaling signaling NN 1446 1454 pathways pathway NNS 1454 1455 . . .